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Background: Automated whole breast ultrasound scanners of the latest generation have reached a level of
comfortable application and high quality volume acquisition. Nevertheless, there is a lack of data concerning this
technology. We investigated the diagnostic performance and inter-observer concordance of the Automated Breast
Volume Scanner (ABVS) ACUSON S2000™ and questioned its implications in breast cancer diagnostics.
Methods: We collected 100 volume data sets and created a database containing 52 scans with no detectable
lesions in conventional ultrasound (BI-RADS®-US 1), 30 scans with benign lesions (BI-RADS®-US 2) and 18 scans with
breast cancer (BI-RADS®-US 5).
Two independent examiners evaluated the ABVS data on a separate workstation without any prior knowledge of
the patients’ histories.
Results: The inter-rater reliability reached fair agreement (κ=0.36; 95% confidence interval (CI): 0.19-0.53). With
respect to the true category, the conditional inter-rater validity coefficient was κ=0.18 (95% CI: 0.00-0.26) for the
benign cases and κ=0.80 (95% CI: 0.61-1.00) for the malignant cases.
Combining the assessments of examiner 1 and examiner 2, the diagnostic accuracy (AC), sensitivity (SE) and
specificity (SP) for the experimental ABVS were AC = 79.0% (95% CI: 67.3-86.1), SE = 83.3% (95% CI: 57.7-95.6) and
SP = 78.1% (% CI: 67.3-86.1), respectively.
However, after the ABVS examination, there were a high number of requests for second-look ultrasounds in up to
48.8% of the healthy women due to assumed suspicious findings in the volume data.
In an exploratory analysis, we estimated that an ABVS examination in addition to mammography alone could
detect a relevant number of previously occult breast cancers (about 1 cancer in 300 screened and otherwise
healthy women).
Conclusions: The ABVS is a reliable imaging method for the evaluation of the breast with high sensitivity and a fair
inter-observer concordance. However, we have to overcome the problem of the high number of false-positive
results. Therefore, further prospective studies in larger collectives are necessary to define standard procedures in
image acquisition and interpretation. Nevertheless, we consider the ABVS as being suitable for integration into
breast diagnostics as a beneficial and reliable imaging method.
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Today, we can expect that more than one million women
will be newly diagnosed with breast cancer each year [1].
The most recent data were reported in 2000, when about
400,000 women died from breast cancer, which repre-
sented 1.6 percent of all female deaths [2]. Nations with
the highest cancer rates include the U.S.A, Italy, Australia,
Germany, the Netherlands, Canada and France [3]. Sec-
ondary prevention, i.e. the early detection of usually cur-
able stages of breast cancer, has moved into the very focus
of all healthcare systems. While the incidence of breast
cancer remains considerably high, we notice a relevant
decline in cancer mortality in numerous countries. This
effort can partly be explained by new and innovative ther-
apies, but there is sound evidence that advances in early
detection probably play the most decisive role [4]. Hence,
the early detection of breast cancer has moved into the
central focus of primary healthcare. This success could
only be achieved because of improvements in imaging
technologies and a higher degree of health awareness.
Breast cancer screening programs are based on radio-
logic examinations of the breast. Additional imaging
modalities are only indicated if suspicious or unclear
findings are present in the mammogram. Mammography
has demonstrated excellent sensitivity, specificity and
inter-observer concordance [5,6]. Nevertheless, the diag-
nostic accuracy of breast ultrasound and magnetic res-
onance imaging (MRI) is as good as mammography.
However, these two modalities imply a number of major
disadvantages. Breast MRI is an expensive and complex
technology. Moreover, MRI has insufficient specificity and,
consequently, produces a relevant number of false-positive
findings. Ultrasound, on the other hand, is observer-
dependent, time-consuming and the examiner has to be
present at the time of image acquisition. Furthermore, only
subjectively chosen screenshots from the ultrasound exam-
ination are printed and/or stored. Mammography has the
advantage that the examination is rapid, standardizable
and cost efficient. The generation of the mammogram can
be performed by medical assistant personnel and the
stored images allow second-readings and follow-ups. How-
ever, merely focusing on detection rates and diagnostic
accuracy, breast ultrasound, breast MRI or even the com-
bination of several imaging technologies may be superior
to mammography alone.
So far, breast ultrasound is the most commonly ac-
cepted and reliable diagnostic method for women with
clinically or radiologically suspicious breast lesions [7].
Furthermore, bilateral whole breast ultrasound has even
demonstrated diagnostic advantages in screening asymp-
tomatic women [8-12]. Nevertheless, after a comparison
of the advantages and disadvantages of the various im-
aging techniques, mammography has become the most
common, reliable and efficient screening method. Thisattitude in breast cancer screening may change someday,
when technical advances allow further improvements of
ultrasound and MRI. At this point, the concept of
automated whole breast ultrasound emerges with the
potential capability to overcome the inherent deficits of
hand-held breast ultrasound. Automated breast scanners
can be easily operated by medical assistants. The stored
volume data allow comfortable and time-efficient evalu-
ation at anytime by a medical professional. The perform-
ance of second-readings by additional examiners and
follow-up evaluations are unproblematic. The concept of
automated breast ultrasound dates back to the 1970s [13].
In the current report, we present data concerning an
up-to-date technology in automated ultrasound, the Auto-
mated Breast Volume Scanner (ACUSON S2000™ ABVS;
Siemens Medical Solutions, Inc., CA, USA). The ABVS re-
constructs 3D data sets of the entire breast volume from
automatically acquired B-mode images. These data can be
stored and analyzed on a separate workstation.
We evaluated whether or not breast lesions, previously
detected by means of conventional ultrasound, could
also be detected and correctly classified by independent
examiners who only used ABVS data. Furthermore, we
analyzed the inter-observer concordance and performed
a model calculation to scrutinize the potential implica-
tions of the ABVS in a screening setting.
Materials and methods
General design and patient database
Our study was carried out at the Franziskus Hospital
Breast Cancer Center in Bielefeld, Germany, between
March 2010 and July 2011. For the ultrasound examina-
tions, we used the Siemens ACUSON S2000™ ultrasound
system with the integrated ABVS (Siemens Medical So-
lutions, Inc., CA, USA). Patients are generally referred
to our outpatient department on account of specific
diagnostic queries, such as palpable breast lesions, breast
pain, suspicious mammograms and intensified screening
in low-risk and high-risk populations. Usually, patients
receive a clinical examination, mammography and con-
ventional breast ultrasound as the standard diagnostic
methods, as well as subsequent examinations whenever
necessary. Additionally, we offer an optional ABVS exam-
ination to all our patients within the routine practice of
our breast cancer center. As a diagnostic standard, ultra-
sound pictures are categorized according to the Breast Im-
aging Reporting and Data System criteria of the American
College of Radiology (ACR BI-RADS®-US) [14]. Study par-
ticipants were recruited from this population. Patients
with a final categorization of BI-RADS®-US 1, 2 or 5 in the
conventional ultrasound examination were regarded as
suitable for our study. BI-RADS®-US categories 0, 3 and 4
involve breast lesions of questionable dignity. As the focus
of our study was on the detection of evidently benign or
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US 0, 3 and 4. Patients with a bra cup size greater than D,
a history of breast surgery, inflammatory conditions of the
breast, skin disorders or psychiatric disorders were also
excluded. Patients who met the inclusion criteria and
agreed to receive an additional ABVS examination entered
our study. In this way, we performed 100 breast examina-
tions with the ABVS and, consequently, we created a data-
base containing 100 3D-scans with BI-RADS®-US 1, 2 or 5
findings in the volume.
All data were obtained using a standard of care clinical
protocol and approved equipment. Therefore, the respon-
sible ethics committee did not demand additional approval
for this non-interventional case study. Although the re-
quirements of individual informed consent were waived,
we decided that all study participants signed an additional
informed consent form before the ABVS examination.
Two independent examiners evaluated the cases from
the anonymized ABVS database. We compared the per-
formance of these two examiners (ABVS, experimental
method) with each other and with the results from the
conventional ultrasound (gold standard).Technical background of the ABVS ultrasound system
For our study we used the ACUSON S2000™ ABVS
(Siemens Medical Solutions, Inc., CA, USA), an ultrasound
system that automatically acquires full-field volumes of theFigure 1 ACUSON S2000™ ABVS. On the left-hand side is the ACUSON S
volume transducer attached to a mechanical arm.breast (Figure 1). The system is equipped with an ultra-
wide linear transducer (Siemens 14L5BV, 14 MHz, 15.4
cm, and 768 piezoelectric elements). While automatically
sweeping over the breast, this ultrasound probe covers a
distance of 16.8 cm in approximately one minute, acquir-
ing about 300 high-resolution slices for post-processing
(resolution: axial = 0.09 mm, lateral = 0.16 mm, sagittal =
0.44 mm). These images are the source for the creation of
the 3D data sets. A separate workstation provides com-
prehensive tools for image analysis and manipulation of
the volume data (Figure 2). The secondary images are
calculated from the acquisition volume in real-time. De-
tails concerning the ABVS have been described else-
where [15,16].Conventional B-mode ultrasound examinations (gold
standard)
Conventional B-mode ultrasound examinations were
performed by the author SW, a DEGUM (Deutsche
Gesellschaft für Ultraschall in der Medizin, German so-
ciety for ultrasound in medicine) level II certified senior
consultant in gynecology with 8 years’ experience in
breast ultrasound [17]. This examiner also knew the
results of the other imaging modalities when available
(mammography, magnetic resonance imaging) and, there-
fore, defined the reference standard for the interpretation
of the volume data sets. The conventional ultrasound2000™ ultrasound machine, on the right-hand side is the 14L5BV
Figure 2 ABVS data on the workstation. This view provides the coronal (left), transverse (upper right) and sagittal (lower right) planes. The
yellow spot marks the position of the nipple. The body marker indicates that this volume was acquired at the apex of the right breast. A plane of
interest can be selected and marked by two orthogonal lines. Then, the corresponding cross-sections are calculated in real-time. Finally, the im-
ages can be optimized by adjusting magnification, brightness and contrast.
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standard linear transducer (Siemens 18 L6 HD, 5.5-18
MHz, 5.6 cm).
After having completed these diagnostic steps, eligible
patients were additionally examined using the ABVS.Figure 3 Predefined positions of the scanner for the left breast that aAccording to the national regulatory authority statutes,
breast US systems have to fulfill basic technical require-
ments and undergo regular quality control measures
[18]. These standards applied to the equipment used in
our study.re used to cover the entire volume.
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The author SW performed the experimental ABVS exam-
ination in order to create 3D data sets. For the ABVS
examination, the patients were in the supine position with
the ipsilateral hand placed on the head. Depending on the
size of the breast, the examiner chose the number of scans
to be taken from each side. Usually, breasts with a bra cup
size A or B can be fully displayed by performing two vol-
ume scans (medial and lateral, Figure 3). In larger breasts,
it is frequently necessary to choose additional views (usu-
ally a separate view of the apex and the axillary process of
the breast).
In order to guarantee sufficient contact with the skin,
a replaceable membrane was attached to the transducer
surface according to the manufacturer’s instructions.
Next, the transducer was positioned on the breast with
slight pressure. An automated scan took between 55 and
65 seconds. Finally, the entire set of volume scans was
sent to the workstation.
Interpretation of the experimental ABVS data by two
independent examiners
The authors SG (examiner 1) and AF (examiner 2) per-
formed the independent interpretation of the ABVS data
sets. Both, SG and AF, are DEGUM level I certified se-
nior residents in gynecology with 5 years’ experience in
breast ultrasound [17].
The independent examiners exclusively analyzed the
volume data sets without any knowledge of the patients’
histories, clinical findings or results of other imaging
modalities. Furthermore, they had no information about
the proportion of BI-RADS®-US 1, 2 and 5 cases in the
database.
The following standard procedure was applied to the
systematic analysis of the ABVS data: Initially, the entire
volume was explored in the coronal plane moving slowly
(i.e. in thin slices) from the skin to the chest wall. During
this process, the examiner marked all mass lesions with
the system’s default tool. Next, the examiner evaluated all
of the selected lesions by displaying them in the sagittalTable 1 Methods
Evaluation in conventional ultrasound (gold standard) BI-RADS®-US
Concerning the performance of the ABVS examination the above scheme was appl
false-negative (FN).and axial planes. Finally, the examiner assigned the lesions
a category according to the ACR BI-RADS®-US system.
Overall interpretation times usually range from 4 to 10
min per case.
Despite the fact that the examiner knew that there
were no BI-RADS®-US 0, 3 or 4 cases in the database, he
was allowed to categorize lesions as BI-RADS®-US 0, 3
or 4 whenever he requested a second-look ultrasound in
order to further assess uncertain lesions.
When a second-look ultrasound was requested for a
lesion that eventually turned out to be benign, the result
of the AVBS examination was defined as “non-concord-
ant” (false-positive). On the other hand, when a second-
look ultrasound was requested for a lesion that turned
out to be malignant, the result was classified as “con-
cordant” (true-positive) because the cancer could then
be correctly detected in the subsequent conventional
ultrasound (Table 1).
Statistical analysis
Microsoft® Office Excel® 2007 (Microsoft Corporation)
was used for data collection.
Statistical analysis was performed by the author SW
using MedCalc® 7.6 statistical software (MedCalc Software
bvba, Belgium) and validated by the other authors.
In order to assess the diagnostic performance of the
ABVS, we calculated sensitivity, specificity and accuracy
for both examiners and used the Z-Test to compare the
performance of examiner 1 with examiner 2. As our
study population did not reflect the real prevalence of
breast cancer, the positive and negative predictive values
were estimated based on the Bayesian theorem using the
reported prevalence of malignancies in screening collec-
tives [19]. For the calculation of the 95% confidence
levels, we used the Newcombe intervals with continuity
correction [20].
The statistical analysis of the extent of agreement be-
tween the two raters was based on Cohen’s Kappa test.
For the interpretation of κ-values we used the magni-
tude guidelines published by Landis and Koch, whoEvaluation of ABVS data (experimental method)
BI-RADS® ABVS
0 1 2 3 4 5
0 n.a. n.a. n.a. n.a. n.a. n.a.
1 FP TN TN FP FP FP
2 FP TN TN FP FP FP
3 n.a. n.a. n.a. n.a. n.a. n.a.
4 n.a. n.a. n.a. n.a. n.a. n.a.
5 TP FN FN TP TP TP
ied to define cases as true-positive (TP), true-negative (TN), false-positive (FP) or
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ment, κ 0–0.20 slight, κ 0.21-0.40 fair, κ 0.41-0.60 mod-
erate, κ 0.61-0.80 substantial, and κ 0.81-1 as almost
perfect agreement [21].
Furthermore, we assessed the correlation between the
expected and the observed rate of second-look ultra-
sounds using the Chi-square test.
Statistical significance was assumed as p < 0.05 for all
tests.
Results
In our study population, the age ranged from 19 to 86
years (median 52 years). According to the BI-RADS®-US
categorization, 52% (n = 52) of our cases were assigned
as BI-RADS®-US 1, 30% (n = 30) had BI-RADS®-US 2 le-
sions and 18% (n = 18) of the cases had BI-RADS®-US 5
lesions. All BI-RADS®-US 5 lesions were confirmed with
histological specimens. The mean tumor size for malig-
nant and benign lesions was 22.0 mm (range 13 to 55)
and 16.7 mm (range 8 to 36), respectively.
Inter-rater reliability
The concordance between examiner 1 and examiner 2
concerning the correct clinical decision of whether the
patient should undergo a control ultrasound due to a
suspicious finding or whether the patient should be
defined as healthy as there is no suspicious lesion is
shown in (Table 2). The inter-rater reliability reachedTable 2 Concordance between examiner 1 and examiner
2 concerning the correct clinical decision of whether the
patient should undergo a control ultrasound due to a
suspicious finding in ABVS (due to BI-RADS® 0,3,4 or 5)
or whether the patient should be defined as healthy as

















0, 3, 4 or 5
(positive)
Total 59 41 100
Distribution of cases by rater and by category. The inter-rater reliability coeffi-
cient calculates to κ = 0.36 (0.19-0.53).
aconcordance between examiner 1 and examiner 2.fair agreement and the Cohen’s Kappa value was κ=0.36
(95% CI: 0.19-0.53).
A more detailed breakdown of the concordance be-
tween examiner 1 and examiner 2 concerning the dis-
tinct BI-RADS® category in the ABVS examination is
given in (Table 3). In this analysis, the inter-rater reliability
also reached fair agreement and the Cohen’s Kappa value
was κ = 0.27 (0.14-0.40).
Inter-rater validity
With respect to the true category (benign cases and malig-
nant cases), the inter-rater validity coefficient calculated to
κ=0.31 (95% CI: 0.21-0.41). Focusing on the benign cases
(n = 82), the conditional inter-rater validity coefficient was
κ=0.18 (95% CI: 0.00-0.26), indicating slight agreement.
Concerning the malignant cases, we found a Cohen’s
Kappa value of κ=0.80 (95% CI: 0.61-1.00), indicating sub-
stantial to almost perfect agreement (Table 4).
Diagnostic performance of the ABVS
The sensitivity for examiner 1 and examiner 2 in detect-
ing malignant lesions with the ABVS was 83.3% (95% CI:
57.7-95.6) and 100% (95% CI: 78.1-100.0), respectively.
The diagnostic accuracy of the method was 71.0% (95%
CI: 60.9-79.4) and 60.0% (95% CI: 49.7-69.5), respect-
ively. The differences between examiner 1 and examiner
2 were statistically not significant. Nevertheless, specifi-
city revealed to be quite low at 68.3% (95% CI: 57.0-
77.9) and 51.2% (40.0-62.3), respectively, as there was a
relevant number of requests for second-look ultrasounds
or further examinations in the group of healthy patients
after the evaluation of the ABVS data. As previously de-
scribed in the methods, these cases had to be classified
as false-positives if there was no cancer (Table 1). More-
over, specificity was significantly different between exam-
iner 1 and examiner 2 (p = 0.001). The detailed results are
shown in (Table 5).
In order to investigate the effect of a second reading of
ABVS data, we performed a tentative analysis and com-
bined the evaluations of examiner 1 and examiner 2. With
respect to the low specificity, the following rules for the
combination of assessments were applied: If both exam-
iners agreed that a scan was suspicious, the evaluation was
considered “positive”. If both examiners agreed that a scan
was unsuspicious or disagreed (and only one examiner
regarded the scan as unsuspicious), the evaluation was con-
sidered “negative”. In this scenario, the accuracy increased
to 79.0% (95% CI: 69.5-86.3), the specificity increased to
78.1% (95% CI: 67.3-86.1) and the sensitivity remained
acceptably high at 83.3% (95% CI: 57.7-95.6) (Table 6).
Rate of second-look ultrasounds
We expected 18 requests for second-look ultrasounds
after the ABVS examination as there were 18 BI-RADS®-
Table 3 Concordance between examiner 1 and examiner 2 concerning the distinct BI-RADS® category in the ABVS
examination
BI-RADS® ABVS BI-RADS® ABVS BI-RADS® ABVS BI-RADS® ABVS
Total1 2 0, 3 or 4 5
(No finding) (Benign finding) (Unclear finding) (Malignant finding)
Examiner 2 (AF)
BI-RADS® ABVS
20a 2 4 2 281
(No Finding)
BI-RADS® ABVS
4 8a 2 0 142
(Benign finding)
BI-RADS® ABVS
14 7 13a 9 430, 3 or 4
(Unclear finding)
BI-RADS® ABVS
4 0 5 6a 155
(Malignant finding)
Total 42 17 24 17 100
Distribution of cases by rater and by detailed BI-RADS® ABVS category. Concerning this detailed evaluation, the inter-rater reliability coefficient calculates to κ =
0.27 (0.14-0.40).
aconcordance between examiner 1 and examiner 2.
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expect requests for the other 82 cases (BI-RADS®-US 1
or 2 lesions). However, the observed rate of second-look
ultrasounds was significantly high, totaling 41 for exam-
iner 1 and 58 for examiner 2, respectively (p < 0.001).
Therefore, the rate of second-look ultrasounds in
healthy women (i.e. BI-RADS®-US 1 and 2) was 31.7%
for examiner 1 and 48.8% for examiner 2.
Regarding the BI-RADS®-US 1 and 2 cases separately,
there was a request for a second-look ultrasound in
33.3% and 53.3% (examiner 1 and examiner 2) of the
women with BI-RADS®-US 2 lesions and in 30.8% and
46.2% of the women with no breast lesions at all (i.e. BI-
RADS®-US 1).
Model calculation and exploratory analysis
Based on our findings, we performed a model calcula-





Benign cases (conventional ultrasound negative) 34a
Malignant cases (conventional ultrasound positive) 0a
Total 34
The inter-rater validity coefficient calculates to κ = 0.31 (95% CI: 0.21-0.41). The con
benign cases and κ=0.80 (95% CI: 0.61-1.00) for the malignant cases.
aconcordance between examiner 1 and examiner 2.could affect the detection rate of cancer in screening
collectives.
As described in the literature, the prevalence of occult
cancer that can be detected by additional ultrasound in
women who already underwent mammography and clin-
ical examination can be estimated to be between 0.3%
and 0.4% [8-12]. Therefore, conventional ultrasound can
detect one cancer in about 250 otherwise healthy women.
Using these numbers, the positive predictive value in
a screening collective would calculate to 1.49% and the
negative predictive value to 99.91%, respectively. There-
fore, the new false-negative rate in a diagnostic setting
using the ABVS would be about 0.09% instead of 0.4%
(Table 7).
If 10,000 women were additionally screened with the
ABVS, we could expect 2,219 positive scans resulting in
the same number of second-look-ultrasounds, finally lead-
ing to 33 detected cancers. Therefore, one cancer wouldgories
miner 1 Examiner 1
negative ABVS positive
Examiner 2 Examiner 2 Examiner 2
Total
ABVS positive ABVS negative ABVS positive
22 8 18a 82
3 0 15a 18
25 8 33 100
ditional inter-rater validity coefficient is κ=0.18 (95% CI: 0.00-0.26) for the
Table 5 Performance of examiner 1 and examiner 2 using
the ABVS data to classify the breast either healthy
(BI-RADS® 1or 2) or suspicious of malignancy (BI-RADS® 0,
3, 4, or 5)
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would be negative, and only seven cancers would be
missed in this group (Figure 4).
Discussion
Primum non nocere
Innovative features for existing medical imaging modal-
ities and even entirely new imaging technologies are
constantly being developed [22,23]. Boosted by the in-
dustry, these technical novelties are rapidly made avail-
able for inpatient and outpatient care. Nevertheless, the
new technologies often lack standardized imaging meth-
odology evaluation and validation studies [24]. There-
fore, the distinct indications for these methods, their
definite diagnostic spectrum and, even more, their po-
tential risk for the patient remain unclear to a certain
degree. A universal principle for medical practice is “pri-
mum non nocere!” translated as “first, do no harm!” [25].
We bear this in mind when we address medical malprac-
tice related to therapeutic interventions. However, mal-
practice can also occur in diagnostic procedures. The
wrong interpretation of diagnostic findings, deficits in
image acquisition, and, in particular, the wrong indication
for a potentially beneficial examination may harm the pa-
tient in terms of unnecessary biopsies or overlooked breast
cancer. Finally, the attending physician is charged with ap-
plying any new method with discernment. A prerequisite
for this responsible utilization of new technologies is a
profound knowledge of the powers and limitations of the
same. Therefore, we encourage the reader to regard anyTable 6 Estimation of the performance of the ABVS in a scena
At least one exam
as normal
Benign cases (conventional ultrasound negative) 6
Malignant cases (conventional ultrasound positive) 3
Total 6
Sensitivity, specificity and accuracy calculate to 83.3%, 78.0% and 79.0%, respective
both examiners agreed that a scan was suspicious, the evaluation was considered “
and only one examiner regarded the scan as unsuspicious, the evaluation was cons
a“true” evaluation.
b“false” evaluation.new imaging technology critically until evident data has
demonstrated a benefit for the patient beyond all doubt.
Concerning the ABVS, such definite data is missing in the
literature, but we regard our own results as a first ap-
proach to approve the ABVS for routine diagnostics.
Performance of the ABVS in our study and in the
literature
The focus of our current study was on the inter-rater
agreement concerning the evaluation of ABVS data. We
were able to demonstrate fair agreement for both the clas-
sification into the categories “positive/negative” (κ=0.36)
and the detailed classification according to the BI-RADS®
system (κ=0.27). Nevertheless, this performance could be
improved. The conditional inter-rater validity coefficients
for benign and malignant cases revealed that the concord-
ance is almost perfect for the malignant cases (κ=0.80),
but only slight for the benign cases (κ=0.18). These results
correlate with the experience, that both examiners reached
high sensitivity (83.3% and nominally 100%, respectively),
but lower specificity (68.3% and 51.2%). In other words,
the detection of malignant lesions can be precisely per-
formed with the ABVS. Cancers are rarely missed with
this technology. The examiners agree in those cases in
which a suspicious lesion is present in the volume data.
On the other hand, the examiners tend to suspect doubt-
ful lesions even in the normal breast tissue of healthy
women. Consequently, the ABVS has a low specificity and
a high false-positive detection rate. This condition impairs
the conditional inter-rater validity for the benign cases
and leads to a high number of unnecessary second-look
ultrasounds. In fact, when the ABVS system is used, we
lose the ability to immediately further explore a question-
able lesion by modifying factors such as compression, the
orientation of the probe and the machine’s setting whilst
acquiring the image in real-time. Ultrasound techniques
such Doppler imaging or sonoelastography cannot be used
either. Because the examiners cannot rely on standardized
interpretation criteria or rules how to handle technical ar-
tifacts in the volume data, they seem to prefer false posi-
tive evaluation rather than missing a malignant lesion.
Nevertheless, with accumulating data, growing experience
and better diagnostic criteria this problem may be solved.rio, where second-reading of the data is performed
iners judges ABVS
(negative)





ly. For the evaluation of the second-reading the following rules were applied: If
positive”. If both examiners agreed that a scan was unsuspicious or disagreed
idered “negative”.
Table 7 Model calculation
Interpretation of the ABVS data by 2 raters
Performance of the ABVS in our study collective (n = 100)
Prevalence of disease 18.00%
SE 83.33%
SP 78.05%
Rate of second look ultrasounds in healthy women (=100%-SP) 21.95%
Estimated performance of the ABVS in a screening collective of asymptomatic women1




Based on our data concerning the performance with two examiners (second-reading of the ABVS data sets), the effect in a screening setting was estimated.
(SE = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; FNR = false negative rate).
1Asymptomatic women are defined as women, who have a normal mammogram and exhibit no symptoms
2As described in the literature, the prevalence of occult carcinomas that can be detected by conventional breast ultrasound can be estimated to be about 0.4%.
This value resembles the theoretical false negative rate (FNR) of clinical examination and mammography alone.
3The new performance values of the ABVS are based upon the estimated prevalence of 0.4% in a screening collective.
4The new false negative rate is based upon a combination of clinical examination, mammography and ABVS in a screening collective.
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formance of an unnecessary second-look ultrasound,
which is expensive, time-consuming and frustrating for
both the patient and the medical professional. How-
ever, this second-look ultrasound implies no direct
harm for the patient. A false-negative result may have a
more serious implication as the diagnosis of malig-
nancy is delayed, with a potentially worse clinical out-
come for the patient.
In conclusion, as the false-negative rate is low we as-
sume high patient safety and encourage the clinical use
of the ABVS for breast diagnostics.Figure 4 Model calculation. Derived from our results, we estimated the e
healthy women.There is only limited data in the literature describing
the inter-observer concordance in lesion detection with
the ABVS:
In 2011, Shin et al. reported on 55 women with 145
breast masses who were examined with handheld ultra-
sound and the ABVS [26]. Five radiologists reviewed the
volume data and detected between 74% and 88% of the
lesions. Substantial agreement was found for BI-RADS®
final assessment category (κ = 0.63).
Recently, Golatta et al. published data on 84 single
breast examinations in 42 women [27]. Six breast diag-
nostic specialists interpreted the 3D-images. Based onffect of an additional ABVS examination in 10.000 otherwise
Table 8 Data in the literature concerning sensitivity (SE)
and specificity (SP) of the ABVS
Author N SE SP
Wojcinski et al. 2011 [15] 50a 100% 52.8%
Lin et al. 2012 [28] 81b 100% 95.0%
Wang HY et al. 2012 [29] 239c 95.3% 80.5%
Wang ZL et al. 2012 [30] 165c 96.1% 91.9%
Current study, Examiner 1 100a 83.3% 68.3%
Current study, Examiner 2 100a 100% 51.2%
avolume data sets (including scans without lesions, BI-RADS®-US 1).
bpatients.
clesions.
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http://www.biomedcentral.com/1471-2342/13/36the BI-RADS® classification the multiple kappa coeffi-
cient was κ = 0.35.
In our analysis, we found fair agreement between the
two examiners, which correlates with the latter results (κ =
0.27). However, more data is needed to evaluate the per-
formance of the ABVS in breast imaging convincingly.
Moreover, there are several reports comparing the ABVS
with hand-held ultrasound [15,28-31]:
The first detailed description of the technical back-
ground and performance of the ABVS was published by
our study group in 2011 [15]. In 2011, 50 ABVS datasets
were evaluated by an independent examiner and accur-
acy, sensitivity and specificity were calculated as 66.0%
(95% CI: 52.9-79.1), 100% (95% CI: 73.2-100) and 52.8%
(95% CI: 35.7-69.2), respectively. Concerning these vari-
ables, our current study yielded comparable results
(Table 5). Nevertheless, as both studies were conducted
in the same institution, a comparison with the results
from other study groups will be of greater interest.
In 2012, Lin et al. published data on 81 patients and
compared ABVS to handheld ultrasound. The authors
described a perfect sensitivity for both methods (ABVS:
100%, hand-held ultrasound: 100%), high specificity
(95.0% and 85.0%, respectively) and, consequently, a high
diagnostic accuracy (97.1% and 91.4%, respectively) [28].
This performance appears extraordinarily high. We sug-
gest that further standardized studies in larger collectives
should investigate if these expectations can be fulfilled.
In the same year, Wang HY et al. studied 239 lesions
in 213 women who were scheduled to undergo biopsy.
In this study, ABVS was similar to hand-held ultrasound
in terms of sensitivity (ABVS: 95.3%, hand-held ultra-
sound: 90.6%), specificity (80.5% and 82.5%, respectively),
and accuracy (85.8% and 85.3%, respectively) [29].
Recently, Wang ZL et al. published data on 153 pa-
tients with 165 breast lesions. The patients underwent
mammography, ABVS and hand-held ultrasound. The
authors reported no significant differences between
ABVS and conventional ultrasound concerning sensitiv-
ity (ABVS: 96.1%, hand-held ultrasound: 93.2%), specifi-
city (91.9% and 88.7%, respectively), and accuracy (94.5%
and 91.5%, respectively) [30,31].
Compared to our data, there is a discrepancy mainly
concerning the specificity, which was lower in our investi-
gation (Table 8). Actually, we had a relevant number of
healthy women without breast lesions (i.e. BI-RADS®-US 1)
in our collective. This condition automatically increases
the false-positive rate and actually reduces specificity.
Hence, the main difference of our study design in
comparison to the above-mentioned studies is that we
did not focus on the evaluation of known lesions alone,
but also on the detection. Therefore, our examiners did
not know whether there was a lesion in the particular
volume or not. In the studies from the literature, theexaminers were well aware, that there is definitely a le-
sion in the volume that requires biopsy (i.e. BI-RADS® 3
and above). This knowledge certainly has an influence
on the evaluation of the lesion and the overall perform-
ance of the ABVS.
Our interpretation: the almost perfect performance of
the ABVS as described in the literature is only valid for
collectives of women with already pre-diagnosed breast
lesions. In realistic collectives that also involve women
without breast lesions (i.e. BI-RADS®-US 1) or with clearly
benign breast lesions (i.e. BI-RADS®-US 2), our data may
be more convincing.
Concerning the inter-observer agreement, Zhang et al.
published data on 234 breast lesions from 208 patients
who were examined with the ABVS [32]. Zhang et al. in-
vestigated the inter-observer agreement concerning the
description of known breast masses according to the BI-
RADS®-US lexicon. They found substantial agreement
for lesion shape, orientation, margin, echo pattern, poster-
ior acoustic features, calcification and final assessment,
and fair agreement for retraction phenomenon and lesion
boundary, respectively. Our study design did not focus the
detailed description of lesions, but we showed fair agree-
ment for the detection of breast masses. This aspect was
not analyzed by Zhang et al.
Furthermore, there are reports in the literature about
the ABVS that concentrate on the optimal scanning
technique [16], the accuracy of measuring the cancer ex-
tent [33] and the detection of lesions located behind the
nipple [34].
Limitations of our study and limitations of the ABVS
All previously mentioned studies have the essential limi-
tation of unicentric design and small patient collectives.
This limitation also applies to our current study. Future
study concepts should include multicenter design and
larger, well-defined patient populations as described else-
where [15]. Furthermore, we compared only two exam-
iners. Although the results demonstrated fair agreement,
the concordance should be confirmed with more ob-
servers. Another limitation of our study is the selection
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on BI-RADS®-US 1, 2 and 5 lesions which causes a cer-
tain bias. Therefore, the proportion of cases to controls
is not representative of the whole population and BI-
RADS®-US 0, 3 and 4 lesions are missing in the study
population. We attempted to overcome this limitation
by conducting a model calculation. Although this ap-
proach is statistically correct, it must be considered that,
due to the small sample size and the vague estimation of
the prevalence, the results must be carefully interpreted.
Moreover, the technology of the ABVS has some limi-
tations per se. As previously described in the literature,
automated breast ultrasound is limited in women with
macromastia and pronounced ptosis [15,16]. In addition,
the ABVS is not capable of scanning the axillary region.
Today, sentinel node biopsy is the standard therapy for
women that were preoperatively staged with a negative
nodal status, which requires ultrasound of the axilla [35].
Furthermore, lymph node alterations may be the first sign
in mammographically and/or sonographically occult breast
cancer or other malignant diseases [36,37]. Therefore, add-
itional conventional ultrasound of the axilla would be
necessary after a suspicious ABVS scan.
Furthermore, we presume that even with optimal scan-
ning technique the peripheral areas of the breast paren-
chyma are not fully covered by the ABVS. Additionally,
shadowing artifacts occur in the retroareolar region and
to a certain extent in the remaining breast volume. There-
fore, a certain proportion of breast parenchyma may be
lost in the volume data. This may reduce the diagnostic
potential in comparison to hand-held ultrasound.
Future implications of the ABVS
Finally, we have to discuss the question of which role the
ABVS could play in future breast cancer diagnosis and
breast cancer screening. Conventional hand-held breast
ultrasound has a commonly accepted role as a comple-
mentary method to mammography, by adding to the
diagnostic accuracy. Despite the well-known advantages,
conventional breast ultrasound is a time-consuming,
examiner-dependent and therefore costly procedure. Fur-
thermore, breast cancer screening with additional breast
ultrasound in low-risk women has not been established, as
data concerning an effect on the overall survival is miss-
ing. Nevertheless, it is evident that breast ultrasound is
capable of detecting previously occult cancers in women
who had already undergone mammography and clinical
examination [8,9,11,12]. However, screening larger collec-
tives with conventional ultrasound is plainly not feasible.
With the ABVS, we have a tool that could principally
overcome these problems, and the ABVS may make ultra-
sound available to a larger number of women. Image ac-
quisition with the ABVS can be efficiently performed by a
medical assistant. Moreover, the ABVS allows a delayedinterpretation of the images at any time, as well as
second-readings. On the other hand, it has to be taken
into account that we still experience a high number of
time-consuming second-look ultrasounds due to the low
specificity. This problem may be solved through second-
readings by an independent examiner. Our proposed rules
are relatively unusual, as, in order to improve the speci-
ficity, disagreement between the examiners would be
classified as “negative” and only agreement that a scan
is suspicious would be classified as “positive”. Therefore,
further studies should include these concepts. However,
we are convinced that the ABVS is a feasible method
that can be easily integrated into the workflow of any in-
patient or outpatient department.
We can imagine the ABVS being applied in breast
cancer screening programs in the future and that add-
itional examinations are offered to women at risk. How-
ever, we still have no data focusing on certain subgroups
of patients (e.g. high-risk versus low-risk, ACR 1–2 ver-
sus ACR 3–4, etc.).
A prospective randomized controlled trial could an-
swer the open questions. This trial should include pa-
tients with normal mammograms, some of whom will
receive additional ABVS. The primary outcome variables
would be the detection rate of breast cancer, the tumor
stage and the overall survival of the two groups. Presum-
ably, results could only be obtained if the collectives
were sufficiently large, which makes it likewise unrealis-
tic that a corresponding trial will actually be conducted.Conclusions
In conclusion, the ABVS has demonstrated high sensitivity
and a fair inter-observer concordance in the evaluation of
breast lesions. However, we have to overcome the problem
of the high number of false-positive results in healthy
women. Therefore, further prospective validation studies
in larger collectives are necessary to define standard pro-
cedures in image acquisition and volume interpretation.
Nevertheless, the ABVS is a reliable, technically mature
and potentially beneficial imaging method. Therefore, we
propose that the ABVS can be used in routine diagnostic
procedures as an adjunct to mammography and conven-
tional ultrasound, as previously described.Competing interests
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